Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis

Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0

Detalles Bibliográficos
Autores principales: Karampitsakos, Theodoros, Papaioannou, Ourania, Dimeas, Ilias, Tsiri, Panagiota, Sotiropoulou, Vasilina, Tomos, Ioannis, Papanikolaou, Ilias C., Katsaras, Matthaios, Kirgou, Paraskevi, Daniil, Zoe, Gourgoulianis, Konstantinos I., Sampsonas, Fotios, Manali, Effrosyni, Papiris, Spyridon, Bouros, Demosthenes, Tzouvelekis, Argyris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990384/
https://www.ncbi.nlm.nih.gov/pubmed/35509438
http://dx.doi.org/10.1183/23120541.00082-2022
Descripción
Sumario:Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0

Ejemplares similares